United States securities and exchange commission logo November 17, 2022 David M. Epstein, Ph.D. Chief Executive Officer Black Diamond Therapeutics, Inc. One Main Street, 14th Floor Cambridge, MA 02142 Re: Black Diamond Therapeutics, Inc. Registration Statement on Form S-3 Filed November 14, 2022 File No. 333-268341 Dear David M. Epstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert E. Puopolo, Esq.